Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 42Lung Neoplasms 39Leukemia, Myeloid, Acute 38Carcinoma, Non-Small-Cell Lung 33Neoplasm Metastasis 29Breast Neoplasms 28Myelodysplastic Syndromes 21Lymphoma, Large B-Cell, Diffuse 20Leukemia, Lymphocytic, Chronic, B-Cell 19Colorectal Neoplasms 18Pancreatic Neoplasms 17Triple Negative Breast Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Multiple Myeloma 15Ovarian Neoplasms 14Glioblastoma 14Carcinoma, Renal Cell 14Squamous Cell Carcinoma of Head and Neck 13Burkitt Lymphoma 13Urinary Bladder Neoplasms 10Mouth Neoplasms 10Melanoma 10Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Carcinoma, Hepatocellular 10Carcinoma 10Oropharyngeal Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Laryngeal Neoplasms 9Brain Neoplasms 9

Interventions

serabelisib 1sapanisertib 1Specimen Handling 1Restraint, Physical 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Carboplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Endometrioid × Specimen Handling × Clear all
NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
81 enrolled
Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡